Pacira BioSciences, Inc. - Common Stock (PCRX)

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships --

- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options -

— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process —— Topline data from Part A of Phase 2 ASCEND study remains on track for end of year —

BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- 

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments --

BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC (“Glass Lewis”) has recommended that Pacira stockholders vote “FOR” each of Pacira’s three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and “AGAINST” all three of DOMA Perpetual Capital Management LLC’s (“DOMA Perpetual” or “DOMA”)1 nominees on the BLUE proxy card ahead of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 9, 2026.

Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position

Issued on behalf of Conexeu Sciences Inc.

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use

Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today

Issued on behalf of Conexeu Sciences Inc.

Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in analyst-led fireside chats at the following three healthcare conferences:

Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on May 4, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results 

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent --

Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today

-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs --

BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after the close of the U.S. markets on Thursday April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

-- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods —

-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion --

-- Issues Statement in Response to DOMA’s Nomination of Director Candidates --